The government does not require the use of a specific test type at this time.

There are three different types of tests – molecular, antigen, and antibody tests. The most common molecular test is the polymerase chain reaction (PCR) test. Molecular and antigen tests are both considered diagnostic tests.

A PCR or antigen test is used to identify an active coronavirus infection. PCR tests detect the COVID-19 virus’ genetic material. The antigen test detects proteins on the surface of the virus.

The antibody tests look for antibodies that are made by a person’s immune system in response to a COVID-19 infection. According to the FDA, antibodies most commonly become detectable 1–3 weeks after symptom onset, at which time evidence suggests that infectiousness is greatly decreased and some degree of immunity from future infection has developed. Antibody tests are commonly used to determine if the test subject has previously had a COVID-19 infection.

All of the available tests are either currently approved under the FDA’s Emergency Use Authorization (EUA) or are pending FDA EUA approval. Tests that are pending EUA have been submitted to the FDA by the manufacturer and are in review by the FDA. In accordance with FDA regulations, tests that are pending EUA approval can be distributed and used in the U.S. under the supervision of a high complexity CLIA licensed laboratory. Our partner has connected with a number of CLIA laboratories to administer any tests that require such oversight.

The Access Bio CareStart COVID-19 Rapid Antigen Test is currently FDA EUA Approved for use in point-of-care settings under a CLIA certificate of waiver. The Boditech COVID-19 Rapid Antibody Test is currently pending FDA EUA approval.

The rapid antigen test has a sensitivity (true positive rate) of 88.3% and a specificity (true negative rate) of 100%. The point-of-care antibody test can identify positive and negative results with an accuracy of 96-97%.

Our partner has established a strategic connection with the manufacturers of the test kits in order to ensure availability of test kits to meet our clients’ needs. We do not currently anticipate any shortages.

The system is completely HIPAA-compliant to ensure the privacy of your employees’ test results.

Depending on your specific needs, our partner can deliver a tailored COVID-19 testing solution which includes any or all of the following components: Rapid COVID-19 test kits and if required, analyzer devices, PCR testing service for confirmatory testing, cloud-based test management platform to facilitate large scale deployments, mobile app for self-service test report access and test scheduling, turnkey mobile on-site testing service, available application integration with client’s enterprise management systems.

Rapid, point-of-care tests use a mucus sample from the nose or throat, but can be analyzed at the doctor’s office or clinic where the sample is collected and results may be available in minutes. These may be molecular or antigen tests.

At-home collection tests allow the patient to collect the sample at home and send it directly to the lab for analysis.

Saliva tests allow a patient to spit into a tube rather than get their nose or throat swabbed. Saliva tests may be more comfortable for some people and may be safer for health care workers who can be farther away during the sample collection.

Once you provide us with a list of your employees and locations (CSV or Spreadsheet) we upload that information into your private instance of our app. Your information is secure on U.S. servers.

HR does not need to enter data into the poral. It is done by the proctor.

You can sign up right away. Onboarding takes 1-2 weeks.